Free Trial
CVE:BCT

BriaCell Therapeutics (BCT) Stock Price, News & Analysis

BriaCell Therapeutics logo
C$10.60 -0.42 (-3.81%)
As of 12/30/2021

About BriaCell Therapeutics Stock (CVE:BCT)

Key Stats

Today's Range
C$10.60
C$11.07
50-Day Range
C$10.60
C$10.60
52-Week Range
C$3.50
C$15.75
Volume
3,402 shs
Average Volume
12,671 shs
Market Capitalization
C$168.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$15.00
Consensus Rating
N/A

Company Overview

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Remove Ads
Receive BCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCT Stock News Headlines

Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
BriaCell Showcases Promising Cancer Treatment Results
BriaCell Shows Promising Survival Data in Cancer Trial
BriaCell Highlights Promising Breast Cancer Trial Results
BriaCell Advances Cancer Treatment with New Trial
See More Headlines

BCT Stock Analysis - Frequently Asked Questions

BriaCell Therapeutics' stock was trading at C$10.60 at the start of the year. Since then, BCT stock has increased by 0.0% and is now trading at C$10.60.
View the best growth stocks for 2025 here
.

Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that BriaCell Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), BMO MSCI India ESG Leaders Index ETF (ZID), Athersys (ATHX), Anavex Life Sciences (AVXL), Gene Biotherapeutics (CRXM) and Inovio Pharmaceuticals (INO).

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
CVE:BCT
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$15.00
High Stock Price Target
C$15.00
Low Stock Price Target
C$15.00
Potential Upside/Downside
+41.5%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$3.34 per share
Price / Cash Flow
3.17
Book Value
C$3.60 per share
Price / Book
2.94

Miscellaneous

Free Float
N/A
Market Cap
C$168.68 million
Optionable
Not Optionable
Beta
N/A
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (CVE:BCT) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners